文献速递胸部肿瘤

生物标志物驱动的经治鳞状非小细胞肺癌治疗:Lung-MAP SWOG S1400 主方案

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
PubMed 文献 · Lancet Oncol · 2020-10-27

Lung-MAP(S1400)是首个由美国国家癌症研究所发起的生物标志物驱动主方案,针对既往接受过铂类化疗的IV期或复发鳞状非小细胞肺癌患者,采用FoundationOne检测进行筛查并分配至生物标志物驱动子研究或非匹配子研究。2014至2019年间共入组1864例患者,1841例提交组织,1674例获得生物标志物结果,1404例获得子研究分配,655例注册子研究。

要点

  • Lung-MAP主方案成功建立生物标志物筛查与快速评估靶向治疗的体系。

核心结论

  • Lung-MAP(S1400)实现了快速回答鳞状非小细胞肺癌生物标志物驱动治疗问题的目标,并已扩展至所有组织学类型及免疫治疗耐药人群。

研究设计与样本

  • 该研究为生物标志物驱动主方案,使用FoundationOne检测进行下一代测序筛查,包含生物标志物驱动子研究和非匹配子研究。
  • 入组标准为年龄≥18岁、IV期或复发鳞状非小细胞肺癌、既往铂类化疗、ECOG体能状态0-2。

主要发现

  • 靶向治疗子研究评估了taselisib(PIK3CA)、palbociclib(细胞周期基因)、AZD4547(FGFR)、rilotumumab联合厄洛替尼(MET)、talazoparib(同源重组修复缺陷)和telisotuzumab vedotin(MET)。
  • 非匹配子研究评估了度伐利尤单抗、纳武利尤单抗联合伊匹木单抗(抗PD-1/PD-L1初治)以及度伐利尤单抗联合替西木单抗(抗PD-1/PD-L1复发)。

临床怎么用

  • 对于既往铂类化疗后的鳞状非小细胞肺癌,应进行生物标志物筛查以指导靶向治疗或免疫治疗选择。
  • 免疫初治患者可考虑含抗PD-1/PD-L1方案,其缓解率和生存期优于靶向治疗或多西他赛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to address an unmet need for better therapies for squamous non-small-cell lung cancer. Lung-MAP (S1400) was created to establish an infrastructure for biomarker screening and rapid regulatory intent evaluation of targeted therapies and was the first biomarker-driven master protocol initiated with the US National Cancer Institute (NCI). METHODS: Lung-MAP (S1400) was done within the National Clinical Trials Network of the NCI using a public-private partnership. Eligible patients were aged 18 years or older, had stage IV or recurrent squamous non-small-cell lung cancer, had previously been treated with platinum-based chemotherapy, and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. The study included a screening component using the FoundationOne assay (Foundation Medicine, Cambridge, MA, USA) for next-generation sequencing, and a clinical trial component with biomarker-driven substudies and non-match substudies for patients who were ineligible for biomarker-driven substudies. Patients were pre-screened and received their substudy assignment upon progression, or they were screened at progression and received their substudy assignment upon completion of testing. Patients could enrol onto additional substudies after progression on a substudy. The study is registered with ClinicalTrials.gov, NCT02154490, and all research related to Lung-MAP (S1400) is completed. FINDINGS: Between June 16, 2014, and Jan 28, 2019, 1864 patients enrolled and 1841 (98·9%) submitted tissue. 1674 (90·9%) of 1841 patients had biomarker results, and 1404 (83·9%) of 1674 patients received a substudy assignment. Of the assigned patients, 655 (46·7%) registered to a substudy. The biomarker-driven substudies evaluated taselisib (targeting PIK3CA alterations), palbociclib (cell cycle gene alterations), AZD4547 (FGFR alteration), rilotumumab plus erlotinib (MET), talazoparib (homologous recombination repair deficiency), and telisotuzumab vedotin (MET). The non-match substudies evaluated durvalumab, and nivolumab plus ipilimumab for anti-PD-1 or anti-PD-L1-naive disease, and durvalumab plus tremelimumab for anti-PD-1 or anti-PD-L1 relapsed disease. Combining data from the substudies, ten (7·0%) of 143 patients responded to targeted therapy, 53 (16·8%) of 315 patients responded to anti-PD-1 or anti-PD-L1 therapy for immunotherapy-naive disease, and three (5·4%) of 56 responded to docetaxel in the second line of therapy. Median overall survival was 5·9 months (95% CI 4·8-7·8) for the targeted therapy groups, 7·7 months (6·7-9·2) for the docetaxel groups, and 10·8 months (9·4-12·3) for the anti-PD-1 or anti-PD-L1-containing groups. Median progression-free survival was 2·5 months (95% CI 1·7-2·8) for the targeted therapy groups, 2·7 months (1·9-2·9) for the docetaxel groups, and 3·0 months (2·7-3·9) for the anti-PD-1 or anti-PD-L1-containing groups. INTERPRETATION: Lung-MAP (S1400) met its goal to quickly address biomarker-driven therapy questions in squamous non-small-cell lung cancer. In early 2019, a new screening protocol was implemented expanding to all histological types of non-small-cell lung cancer and to add focus on immunotherapy combinations for anti-PD-1 and anti-PD-L1 therapy-relapsed disease. With these changes, Lung-MAP continues to meet its goal to focus on unmet needs in the treatment of advanced lung cancers. FUNDING: US National Institutes of Health, and AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Genentech, and Pfizer through the Foundation for the National Institutes of Health.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020. PMID: 33125909. doi:10.1016/S1470-2045(20)30475-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。